[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"case:lead-pharma-medicine-bv-09172969:header:guest:personal:":3,"case:lead-pharma-medicine-bv-09172969:investigations:guest:personal::{}":79},{"id":4,"slug":5,"name":6,"trade_names":7,"status":8,"procedure":9,"procedure_type":10,"insolvency_number":29,"case_number":29,"declared_on":30,"terminated_on":31,"termination_reason":32,"kvk_number":33,"legal_form":34,"sbi":14,"court":37,"judge":40,"judge_source":41,"curator":42,"location":46,"counts":56,"pages":61,"follower_count":60,"report_count":57,"last_report_on":73,"last_update_at":74,"freshness":75,"linked":78},"01M3SJFSJCWBFFNRZ7ERDWZQ0C","lead-pharma-medicine-bv-09172969","Lead Pharma Medicine B.V.",[],"terminated","bankruptcy",{"id":11,"key":9,"family":12,"name":13,"short_name":14,"legal_basis":15,"features":19},"01M3Y8CPCPT53NPXHK39BWK1QY","insolvency","Faillissement",null,{"name":16,"provision":17,"url":18},"Faillissementswet","Titel I (art. 1 e.v.)","https:\u002F\u002Fwetten.overheid.nl\u002FBWBR0001860",[20,21,22,23,24,25,26,27,28],"reports","financials","creditors","assets","investigations","curator_workspace","appointments","court_decisions","portfolio_monitoring","F.01\u002F25\u002F159","2025-06-17","2026-09-29","lack_of_assets","09172969",{"value":35,"source":36},"BV","cir",{"name":38,"slug":39,"location":14},"Rechtbank Oost-Brabant","oost-brabant","mr. S.C.E.F. Moulen Janssen",{"type":36,"report_number":14,"published_on":14},{"name":43,"slug":44,"law_firm":14,"city":14,"verified":45},"mr. D.P. Schalken","dp-schalken",false,{"street":47,"house_number":48,"addition":49,"postal_code":50,"city":51,"municipality":51,"province":52,"lat":53,"lng":54,"kind":55,"source":36},"Kloosterstraat","9","RK","5349AB","Oss","Noord-Brabant",51.760717,5.533719,"business",{"reports":57,"documents":58,"assets":59,"investigations":60,"news":60},9,13,6,0,{"overview":62,"reports":64,"financials":65,"investigations":66,"assets":67,"timeline":68,"documents":69,"news":70,"company":71,"compare":72},{"index":63,"ads":63},true,{"index":63,"ads":63},{"index":63,"ads":63},{"index":45,"ads":45},{"index":63,"ads":45},{"index":63,"ads":45},{"index":63,"ads":45},{"index":45,"ads":45},{"index":63,"ads":45},{"index":45,"ads":45},"2026-08-11","2026-10-04T17:34:33+00:00",{"last_checked_at":76,"last_reconciled_at":76,"stale":45,"status":77},"2026-10-11T04:06:37+00:00","current",{"continued_from":14,"continued_as":14},{"data":80,"meta":204},[81,113,126,136,151,164,176,184,191],{"topic":82,"state":83,"category":84,"states":85,"source":99},"legality_review","mentioned","automated",[86,90,93,96],{"report_number":87,"report_date":88,"state":89},1,"2025-07-14","investigating",{"report_number":91,"report_date":92,"state":89},2,"2025-10-14",{"report_number":94,"report_date":95,"state":89},3,"2026-01-14",{"report_number":97,"report_date":98,"state":83},4,"2026-04-08",{"id":100,"category":84,"method":101,"source_type":102,"document":103,"page":108,"section":109,"excerpt":110,"certainty":111,"curator_verified_at":14,"processed_at":112},318138,"deterministic","cir_report",{"id":104,"title":105,"report_number":97,"report_date":98,"published_on":98,"page_count":106,"url":107,"available":63},"01M3SJG6EV72GZJ4NWXZ6V4RQB","Verslag: 08-04-2026",17,"https:\u002F\u002Ffaillissement.app\u002Fdocuments\u002F01M3SJG6EV72GZJ4NWXZ6V4RQB.pdf",11,"7.1 Boekhoudplicht","Voldaan.",0.5,"2026-10-02T18:43:03+00:00",{"topic":114,"state":83,"category":84,"states":115,"source":120},"director_liability",[116,117,118,119],{"report_number":87,"report_date":88,"state":89},{"report_number":91,"report_date":92,"state":89},{"report_number":94,"report_date":95,"state":89},{"report_number":97,"report_date":98,"state":83},{"id":121,"category":84,"method":101,"source_type":102,"document":122,"page":123,"section":124,"excerpt":125,"certainty":111,"curator_verified_at":14,"processed_at":112},318136,{"id":104,"title":105,"report_number":97,"report_date":98,"published_on":98,"page_count":106,"url":107,"available":63},12,"7.5 Onbehoorlijk bestuur","Toelichting Er is geen sprake van onbehoorlijk bestuur. De gemaakte intercompany-afspraken over de toebedeling van kosten en activa binnen het concern w erd achterhaald door het uitgesproken faillissement van Lead Pharma Holding B.V.",{"topic":127,"state":83,"category":84,"states":128,"source":133},"bookkeeping_duty",[129,130,131,132],{"report_number":87,"report_date":88,"state":89},{"report_number":91,"report_date":92,"state":89},{"report_number":94,"report_date":95,"state":89},{"report_number":97,"report_date":98,"state":83},{"id":134,"category":84,"method":101,"source_type":102,"document":135,"page":108,"section":109,"excerpt":110,"certainty":111,"curator_verified_at":14,"processed_at":112},318135,{"id":104,"title":105,"report_number":97,"report_date":98,"published_on":98,"page_count":106,"url":107,"available":63},{"topic":137,"state":138,"category":84,"states":139,"source":144},"annual_accounts_filing","completed",[140,141,142,143],{"report_number":87,"report_date":88,"state":138},{"report_number":91,"report_date":92,"state":138},{"report_number":94,"report_date":95,"state":138},{"report_number":97,"report_date":98,"state":138},{"id":145,"category":84,"method":101,"source_type":102,"document":146,"page":123,"section":147,"excerpt":148,"certainty":149,"curator_verified_at":14,"processed_at":150},134817,{"id":104,"title":105,"report_number":97,"report_date":98,"published_on":98,"page_count":106,"url":107,"available":63},"7.2 Depot jaarrekeningen","De jaarrekening 2023 is gedeponeerd op 4 juli 2024.",0.7,"2026-09-30T16:31:29+00:00",{"topic":152,"state":138,"category":84,"states":153,"source":158},"causes_investigation",[154,155,156,157],{"report_number":87,"report_date":88,"state":138},{"report_number":91,"report_date":92,"state":138},{"report_number":94,"report_date":95,"state":83},{"report_number":97,"report_date":98,"state":138},{"id":159,"category":84,"method":101,"source_type":102,"document":160,"page":161,"section":162,"excerpt":163,"certainty":149,"curator_verified_at":14,"processed_at":150},134802,{"id":104,"title":105,"report_number":97,"report_date":98,"published_on":98,"page_count":106,"url":107,"available":63},5,"1.5 Oorzaak faillissement","Tot heden is de curator het volgende gebleken uit gesprekken met het bestuur en betrokkenen, maar dit vormt geen conclusie. Lead Pharma Medicine B.V. exploiteert een farmaceutisch onderzoeks- en ontw ikkelbedrijf. Daartoe verricht zij onderzoek naar nieuw e medicijnen ter genezing van kanker en auto-immuunziekten. Medicijnonderzoek is een langdurig en kostbaar traject. Van een idee naar verkoop du",{"topic":165,"state":83,"category":84,"states":166,"source":171},"paulianas",[167,168,169,170],{"report_number":87,"report_date":88,"state":89},{"report_number":91,"report_date":92,"state":89},{"report_number":94,"report_date":95,"state":89},{"report_number":97,"report_date":98,"state":83},{"id":172,"category":84,"method":101,"source_type":102,"document":173,"page":123,"section":174,"excerpt":175,"certainty":111,"curator_verified_at":14,"processed_at":112},318137,{"id":104,"title":105,"report_number":97,"report_date":98,"published_on":98,"page_count":106,"url":107,"available":63},"7.6 Paulianeus handelen","Nee Toelichting Er is geen sprake van paulianeus handelen.",{"topic":177,"state":178,"category":14,"states":179,"source":14},"related_party_transactions","not_mentioned",[180,181,182,183],{"report_number":87,"report_date":88,"state":178},{"report_number":91,"report_date":92,"state":178},{"report_number":94,"report_date":95,"state":178},{"report_number":97,"report_date":98,"state":178},{"topic":185,"state":178,"category":14,"states":186,"source":14},"fraud_report",[187,188,189,190],{"report_number":87,"report_date":88,"state":178},{"report_number":91,"report_date":92,"state":178},{"report_number":94,"report_date":95,"state":178},{"report_number":97,"report_date":98,"state":178},{"topic":192,"state":83,"category":84,"states":193,"source":198},"proceedings",[194,195,196,197],{"report_number":87,"report_date":88,"state":83},{"report_number":91,"report_date":92,"state":83},{"report_number":94,"report_date":95,"state":83},{"report_number":97,"report_date":98,"state":83},{"id":199,"category":84,"method":101,"source_type":102,"document":200,"page":201,"section":202,"excerpt":203,"certainty":111,"curator_verified_at":14,"processed_at":150},134820,{"id":104,"title":105,"report_number":97,"report_date":98,"published_on":98,"page_count":106,"url":107,"available":63},16,"9.1 Naam wederpartijen","Er is niet gebleken van procedures.",{"reports":205},[206,208,210,212],{"id":207,"number":87,"published_on":88},"01M3SJFV54Q9T37PDS1XMEDQEQ",{"id":209,"number":91,"published_on":92},"01M3SJFWV1HQCMXQDQAEJZ5HED",{"id":211,"number":94,"published_on":95},"01M3SJFZZX1K9WBY6WZ9W86CVW",{"id":213,"number":97,"published_on":98},"01M3SJG4ZHENMD35XVB72FSVJQ"]